Sym004, a novel anti-EGFR antibody mixture augments radiation response in human lung and head and neck cancers

類似資料

• Sym004, a Novel EGFR Antibody Mixture, Can Overcome Acquired Resistance to Cetuximab
  著者:: Iida, Mari, 等
  出版事項: (2013)
• Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation
  著者:: Huang, Shyhmin, 等
  出版事項: (2012)
• Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models
  著者:: Keir, Stephen T., 等
  出版事項: (2018)
• Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines
  著者:: Fukuoka, Shota, 等
  出版事項: (2016)
• Phase I dose‐escalation trial of Sym004, an anti‐EGFR antibody mixture, in Japanese patients with advanced solid tumors
  著者:: Kojima, Takashi, 等
  出版事項: (2018)